Nasdaq · CIK 0001938046
MGRX MANGOCEUTICALS, INC.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $0.42 on Oct 9, 2026, +160% from the 52-week low and -85% from the high.
MANGOCEUTICALS, INC. (MGRX) has 20 SEC Form 4 filings on file from 6 insiders, the latest filed on Oct 6, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at MGRX. The newest: Eugene M Johnston (CFO) sold $3,884 of stock on Dec 15, 2025, filed Dec 17, 2025, scored 22 (weak). The largest of the 4 shown: Alex P. Hamilton (director) sold $153k on Nov 19, 2025, scored 46 (moderate).
MGRX closed at $0.42 on Oct 9, 2026, 160% above its 52-week low and 85% below its 52-week high.
2 Form 144 notices of planned sales are on file, the latest filed Dec 3, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MANGOCEUTICALS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Eugene M Johnston CFO sell | $3,884 3,333 shares | -3% | - | |
| 22Weak | Eugene M Johnston CFO sell | $5,975 5,000 shares | -4% | - | |
| 22Weak | Eugene M Johnston CFO sell | $11k 10,000 shares | -7% | - | |
| 46Moderate | Alex P. Hamilton director sell | $153k 125,000 shares | -97% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 3, 2025 | JOHNSTON EUGENE M Officer | 128,333 0.92% of outstanding | $149k | Dec 3, 2025 | none |
| Nov 19, 2025 | Hamilton Alex P. Director | 125,000 0.90% of outstanding | $155k | Nov 19, 2025 | none |
Transactions
Every row filed, 35 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | Alex P. Hamilton director | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 101,667 | 7 d ago |
| Jul 28, 2026 | Eugene M Johnston CFO | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 220,000 | 7 d ago |
| Sep 30, 2025 | Jacob D. Cohen Chief Executive Officer | GGift Common Stock | -500,000 | $0.00 | $0 | 0 | 7 d ago |
| Sep 30, 2025 | Jacob D. Cohen Chief Executive Officer | GGift Common Stock | +500,000 | $0.00 | $0 | 1,305,000 | 7 d ago |
| Jul 28, 2026 | Jacob D. Cohen Chief Executive Officer | AGrant or award Common Stock | +2,000,000 | $0.00 | $0 | 2,000,000 | 7 d ago |
| Aug 11, 2026 | Jacob D. Cohen Chief Executive Officer | GGift Common Stock | -2,000,000 | $0.00 | $0 | 0 | 7 d ago |
| Aug 11, 2026 | Jacob D. Cohen Chief Executive Officer | GGift Common Stock | +2,000,000 | $0.00 | $0 | 3,305,000 | 7 d ago |
| Dec 19, 2025 | Jacob D. Cohen Chief Executive Officer | JOther Convertible Promissory Notederivative | - | $0.00 | - | - | 7 d ago |
| Jun 5, 2025 | Jacob D. Cohen Chief Executive Officer | GGift Common Stock | -200,000 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Jun 5, 2025 | Jacob D. Cohen Chief Executive Officer | GGift Common Stock | +200,000 | $0.00 | $0 | 805,000 | Mar 20, 2026 |
| Sep 9, 2025 | Jacob D. Cohen Chief Executive Officer | AGrant or award Common Stock | +500,000 | $0.00 | $0 | 500,000 | Mar 20, 2026 |
| Mar 16, 2026 | Jacob D. Cohen Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Jul 21, 2025 | Jacob D. Cohen Chief Executive Officer | AGrant or award Convertible Promissory Notederivative | - | - | - | - | Mar 20, 2026 |
| Mar 16, 2026 | Jacob D. Cohen Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 20, 2026 |
| Jul 21, 2025 | Jacob D. Cohen Chief Executive Officer | AGrant or award Warrant to Purchase Common Stockderivative | +50,000 | - | - | 50,000 | Mar 20, 2026 |
| Mar 16, 2026 | Jacob D. Cohen Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -83,333 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Sep 9, 2025 | Jacob D. Cohen Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Mar 20, 2026 |
| Mar 16, 2026 | Jacob D. Cohen Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +83,333 | $0.00 | $0 | 83,333 | Mar 20, 2026 |
| Mar 16, 2026 | Jacob D. Cohen Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -2,000,000 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Mar 16, 2026 | Jacob D. Cohen Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Mar 20, 2026 |
| Dec 15, 2025 | Eugene M Johnston CFO | SOpen-market sale Common Stock | -3,333 | $1.17 | $3,884 | 120,000 | Dec 17, 2025 |
| Dec 9, 2025 | Eugene M Johnston CFO | SOpen-market sale Common Stock | -5,000 | $1.20 | $5,975 | 123,333 | Dec 11, 2025 |
| Dec 5, 2025 | Eugene M Johnston CFO | SOpen-market sale Common Stock | -10,000 | $1.13 | $11k | 128,333 | Dec 9, 2025 |
| Nov 19, 2025 | Alex P. Hamilton director | SOpen-market sale Common Stock | -125,000 | $1.22 | $153k | 3,334 | Nov 26, 2025 |
| Apr 10, 2025 | Jacob D. Cohen Chief Executive Officer | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 200,000 | Sep 30, 2025 |
| Sep 9, 2025 | Kenny Myers director | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 136,667 | Sep 12, 2025 |
| Sep 9, 2025 | Eugene M Johnston Chief Financial Officer | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 138,334 | Sep 12, 2025 |
| Sep 9, 2025 | Alex P. Hamilton director | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 126,667 | Sep 12, 2025 |
| Sep 9, 2025 | Lorraine Pamela D'Alessio director | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 136,667 | Sep 12, 2025 |
| Apr 10, 2025 | Jacob D. Cohen Chief Executive Officer | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 200,000 | Apr 11, 2025 |
| Apr 10, 2025 | Lorraine Pamela D'Alessio director | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 36,667 | Apr 11, 2025 |
| Apr 10, 2025 | Alex P. Hamilton director | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 28,334 | Apr 11, 2025 |
| Apr 10, 2025 | Antonios Isaac President | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 60,000 | Apr 11, 2025 |
| Apr 10, 2025 | Kenny Myers director | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 36,667 | Apr 11, 2025 |
| Nov 11, 2024 | Eugene M Johnston Chief Financial Officer | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 38,334 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jacob D. CohenChief Executive Officer
- Lorraine Pamela D'Alessiodirector
- Alex P. Hamiltondirector
- Antonios IsaacPresident
- Eugene M JohnstonCFO
- Kenny Myersdirector
Questions about MGRX
Answered from the filings on this page, as of the latest one.
Are insiders buying MGRX?
No. In the last 90 days no insider at MANGOCEUTICALS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MGRX on the open market?
Eugene M Johnston (CFO) sold $3,884 of MGRX on Dec 15, 2025 and filed the Form 4 on Dec 17, 2025. InsiderTell scored 22 (weak).
How many insiders file Form 4 at MANGOCEUTICALS, INC.?
6 people have filed a Form 4 at MANGOCEUTICALS, INC., among them Jacob D. Cohen (Chief Executive Officer), Lorraine Pamela D'Alessio (director), Alex P. Hamilton (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.